eISSN: 1644-4124
ISSN: 1426-3912
Central European Journal of Immunology
Current issue Archive Manuscripts accepted About the journal Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
SCImago Journal & Country Rank
vol. 43
Review paper

Antigenic and immunogenic properties of chondrocytes. Implications for chondrocyte therapeutic transplantation and pathogenesis of inflammatory and degenerative joint diseases

Anna Osiecka-Iwan
Anna Hyc
Dorota M. Radomska-Leśniewska
Adrian Rymarczyk
Piotr Skopiński

(Centr Eur Immunol 2018; 43 (1): 209-219)
Online publish date: 2018/06/30
Article file
Get citation
JabRef, Mendeley
Papers, Reference Manager, RefWorks, Zotero


Clinical application of chondrocyte transplants and possible involvement of chondrocyte antigens in rheumatoid arthritis (RA) and other inflammatory joint diseases stimulated enormously studies on the expression of class I and II major histocompatibility complex (MHC) molecules by chondrocytes as well as expression of other chondrocyte surface molecules that might stimulate antibody production. Thus, it appeared that the short recapitulation of the present status of chondrocyte as a player in joint surface reconstruction, and possibly the villain in inflammatory joint disease, would be indicated. Because the first chondrocyte transplants were done in our laboratory [1] and our review covering various aspects of chondrocyte antigenicity published in 2002 [2] is now obsolete, we felt that we should write a new survey of these topics as a continuation of laboratory tradition.

Cartilage as immunoprivileged tissue

In physiological conditions chondrocytes are sequestrated from the cells of the immune system by extracellular matrix, and transplanted fragments of allogeneic cartilage are not rejected [3]. However, in inflammation processes, after trauma or after transplantation of isolated allogeneic chondrocytes, their surface molecules are exposed to the contact with immunocompetent cells, and chondrocytes initiate the immune response [2, 4]

Major histocompatibility complex (MHC) molecules expression on chondrocytes

Isolated chondrocytes transplanted into autogenic, syngeneic, or allogeneic hosts formed cartilage similar to that from which they originate [1, 5]. Syngeneic chondrocyte grafts did not show any signs of rejection [6, 7], but cartilage produced by allogeneic chondrocytes evoked the immune response of the recipient and was gradually destroyed [8, 9]. Immunisation by allogeneic chondrocytes could be induced by MHC molecules present on the surface of chondrocytes [10, 11]. The presence of MHC class I molecules (also called human leukocyte antigens HLA-A, HLA-B, HLA-C) has been found on the surface of human chondrocytes derived from healthy individuals [12-14]. The expression of MHC class II molecules was observed on the surface of normal rabbit articular chondrocytes [11]. Malejczyk and Romaniuk [15] found that rat articular chondrocytes expressed MHC class II molecules encoded by the RT1D subregion without the presence of molecules encoded by the RT1B subregion. Human unstimulated articular and nasal chondrocytes have been shown to lack MHC class II molecules [12, 14, 16-18]. Expression of these molecules could be induced in vitro under the influence of pro-inflammatory cytokines, for example interferon- (IFN-) [12, 14, 16, 19], and in vivo, in the course of the rejection of transplanted allogeneic cartilage [17]. Moreover, the presence of MHC class II molecules (HLA-DR, HLA-DP, HLA-DQ) was found on the surface of human articular chondrocytes from patients with rheumatoid arthritis (RA) and osteoarthritis (OA), but they did not occur on the surface of chondrocytes in patients with osteochondroma [12, 20]. Abe et al. [21] demonstrated, that chondrocytes from osteoarthritic knees expressed MHC class I molecules, but only 1 to 2% of chondrocytes expressed MHC class II molecules.
The presence of class II MHC molecules, usually found on professional antigen presenting cells, could allow chondrocytes to present antigens to T cells. It has been shown that rabbit isolated articular chondrocytes preincubated with ovalbumin have been able to present ovalbumin to lymph node cells obtained from rabbits immunised with this protein [11]. A similar effect was observed also for human articular and nasal chondrocytes which, after stimulation with IFN-, presented tetanus toxoid and were able to stimulate proliferative response of T lymphocytes [17, 22].
Monoclonal antibody evaluation of cells infiltrating the allocartilage in rats showed that the main cells actively participating in cartilage destruction were monocytes/macrophages and cytotoxic T and natural killer (NK) cells [9]. Moreover, RT1.B class II MHC molecules appeared on some chondrocytes after transplantation to an allogeneic recipient, and their expression increased in the course of rejection and could be associated with the activity of pro-inflammatory cytokines produced by infiltrating cells [15]. This expression, necessary for the presentation of antigens, might be important for initiation of the specific immune response and might explain the strong reaction to isolated allogeneic chondrocyte transplants [16, 17, 20].

Natural cytotoxicity against chondrocytes

Natural killer cells may play an important role in the rejection of transplanted isolated chondrocytes and in cartilage destruction observed in the course of inflammatory joint diseases. Spontaneous cytotoxic reactivity was observed against isolated mice epiphyseal and rat epiphyseal, costal, nasal, and auricular chondrocytes [23, 24]. Similar, but weaker, cytotoxicity against human chondrocytes isolated from mature articular cartilage has also been observed by Yamaga [25]. The activity of NK cells in the rejection of transplanted isolated chondrocytes was confirmed by Sommaggio et al. [26]. They discovered that cytotoxic activity of NK cells against chondrocytes was associated with the expression on chondrocyte ligands for human NK cells – natural cytotoxicity triggering receptor 3 (NKp30, CD337) and natural cytotoxicity triggering receptor 1 (NKp46, CD335), and that the adhesion of NK cells and chondrocytes was regulated by pro-inflammatory cytokines and was dependent on the expression of vascular cell adhesion molecule 1 (VCAM-1, CD106) and intercellular adhesion molecule 1 (ICAM-1, CD54) on chondrocytes. Additionally, constitutive expression of ligand for NK cell natural cytotoxicity triggering receptor 2 ligand (NKp44L) by normal human articular chondrocytes was confirmed by Białoszewska et al. [27]. NKp30, NKp44 (CD336), and NKp46 are natural cytotoxicity receptors (NCRs) of NK cells, which can bind some ligands on the surface of target cells, for example highly charged HS/heparin structures [28].
NK cells are also involved in the cartilage destruction process in the course of inflammatory autoimmune diseases [25, 29, 30]. Yamaga et al. [25] studied the capability of lymphocytes from healthy individuals and patients with arthritis to lyse chondrocytes. They found that peripheral blood mononuclear cells (PBMC) from healthy individuals possessed only a low ability to lyse chondrocytes, whereas cells from the synovial fluid of patients with RA showed lytic activity toward chondrocytes. This chondrolytic activity of lymphocytes was greatly increased by interleukin-2 (IL-2). In contrast, treatment of chondrocytes with IFN-, which enhanced MHC class I and II gene expression, decreased the susceptibility of chondrocytes to lysis. The activity of NK in the pathogenesis of inflammatory joint diseases was confirmed by Dalbeth and Callan [29], who observed NK cells present within inflamed joints.
The mechanisms responsible for recognition of chondrocytes by NK cells during cartilage destruction observed in inflammatory joint diseases are still poorly understood. Białoszewska et al. [31] found that chondrocyte sensitivity to lysis by NK cells was dependent on the chondrocyte-specific phenotype of target cells. The authors showed that the lysis of rat epiphyseal chondrocytes was regulated by the surface expression of chondroitin sulphate, one of proteoglycans reported as a ligand for NK cell receptors [32]. The same group of researchers [33] found that IL-2 stimulated human articular chondrocyte expressed lectin-like transcript-1 (LLT1) molecules. Interactions between killer cell lectin-like receptor subfamily B member 1 (NKR-P1A, CD161) on NK cells and LLT1 on target cells inhibited NK cell-mediated cytotoxicity [33, 34].

Immunogenic properties of chondrocytes – implications for chondrocyte therapeutic transplantation

Autologous chondrocyte transplantation

The capacity of articular cartilage to repair is limited, and cartilage injuries that reach subchondral bone are usually filled by fibrous tissue formed by cells migrating from bone marrow [35, 36]. For the first time, autogenic articular chondrocytes isolated from the non-weight-bearing areas of cartilage and expanded in vitro have been used for treatment of patients with deep articular cartilage defects [37]. This method has been constantly modified in recent years, and cultured autogenic chondrocytes have been successfully applied for healing articular cartilage defects in humans [38, 39]. Some new methods are associated with the use of cell-seeded scaffolds, for example matrix-associated autologous chondrocyte transplantation/implantation (MACT/MACI), a new operation procedure using a cell-seeded collagen matrix applied for the treatment of localised full-thickness cartilage defects [40, 41]. The use of chondrocytes for the treatment of patients with deep articular cartilage defect is hampered. Chondrocytes liberated from cartilage matrix and placed in monolayer culture undergo a transition from chondrocyte phenotype to fibroblastoid phenotype. They change the profile of the macromolecules produced by suppressing collagen type II and proteoglycan synthesis and by the concomitant expression of collagen type I [42-45]. Transplantation of these dedifferentiated cells into cartilage defect causes the growth of fibrous cartilage [46]. These changes can be reverted by transferring chondrocytes from monolayer to 3-D culture in agarose gel [47], alginate beads [48], or on the surface coating with collagen type I or IV [49].

Allogeneic chondrocyte transplantation

It is necessary to emphasise the basic disadvantages of autogenic chondrocyte transplantation – the need for surgical intervention and the limited availability of autogenic cells, especially in older donors. Allogeneic chondrocytes are more accessible, but cartilage produced by them in articular surface defects in rats was resorbed by infiltrating immune cells [50, 51]. This acute rejection of newly formed allocartilage was not prevented even by the strong immunosuppressive agents cyclosporine A (CsA) and cladribine (2-chlorodeoxyadenosine) [52]. Allogeneic cartilage formed by chondrocytes transplanted into articular cartilage defects was infiltrated in its deep part, submerged in subchondral bone and bone marrow, while on the surface of the transplant facing the joint cavity infiltrating cells were absent [50, 52]. This suggested that immunisation of recipients occurred via the contact of chondrocytes with bone marrow cells. Moskalewski et al. [53] showed, that separation of transplanted allogeneic chondrocytes from the contact with bone marrow cavity prevented immunisation of recipients and the cartilage remained free of infiltration.
In subsequent studies, it was shown that cartilage formed by transplanted syngeneic chondrocytes in joint surface defects or intramuscularly was rejected in animals sensitised with allogeneic chondrocytes. These transplants were infiltrated by CD8+ lymphocytes, which accumulated close to the transplants and invaded only their peripheral part, and the macrophages penetrating into the transplants [7, 54]. The rejection of cartilage formed by syngeneic chondrocytes transplanted into sensitised recipients might indicate the presence surface tissue-specific chondrocyte antigens.

Tissue-specific chondrocyte antigens

The expression of tissue-specific chondrocyte antigen(s) has been suggested since Langer et al. [55] found that rats injected with syngeneic chondrocytes developed autoreactivity, assayed by leukocyte migration test. Lately it has been shown that both rat allogeneic and syngeneic chondrocytes stimulated proliferation of lymphocytes in mixed lymphocyte-chondrocyte cultures [56, 57], and these observations were confirmed with human, bovine, and canine cells [58]. Furthermore, Malseed and Heyner [59] and Lance at al. [57] reported that sera from rabbits immunised with rat chondrocytes contained specific antibodies against chondrocytes, and these immunoglobulins showed cross-reactivity with syngeneic chondrocytes [57].
In subsequent years, it has been found that in patients with RA and OA, different types of antibodies react specifically with the chondrocyte surface [17, 60-62]. Some of these antibodies are directed against type II collagen [63], as well as types IX and XI [17], suggesting the presence of a collagen molecule on the surface of chondrocytes. Among the theories explaining the presence of collagen on the surface of chondrocytes, the most likely assumption is that collagen molecules are bound to the cell membrane by the appropriate receptors [63]. Several potential collagen receptors have been detected on the surface of the chondrocytes. One of them is anchorin C II, a 31 kDa glycoprotein, belonging to the annexin family, which may bind type I, II, III, V and X collagen [64, 65]. Another receptor for collagen is colligin, a 47 kDa glycoprotein that can bind to collagen type I and IV [66]. Other molecules that are candidates for collagen membrane receptors are syndecan [67], chondronectin [68] and integrins [69].
Another group of antibodies present in RA and OA patients are antibodies that do not react with type II collagen but are directed against other chondrocyte surface proteins, which can be considered as tissue-specific chondrocyte antigens. It has been shown that about 32% of the sera of the RA patients contained antibodies, which reacted with antigens expressed exclusively by chondrocytes, and 75% of these sera contained antibodies against antigens expressed by both chondrocytes and fibroblasts [70]. These surface molecules could act as targets in inflammatory joint diseases.

Chondrocyte antigens as potential targets in inflammatory joint diseases

Cartilage-specific membrane antigen (CH65)

One such chondrocyte surface molecule is serine and asparagine-rich peptide, with a molecular weight of 65 kDa (CH65). The CH65 antigen was detected in about 60-70% of sera of RA patients [71]. It was a chondrocyte-specific constitutively expressed autoantigen. CH65 displayed high homology with cytokeratins and the HSP65 – small heat shock protein that functions as a chaperone protein probably maintaining denatured proteins in a folding-competent state [61, 72, 73]. PBMC of 50% of the RA patients exhibited strong proliferative response to CH65 in culture, contrary to PBMC of healthy donors. Moreover, CH65-stimulated RA PBMC produced interleukin-1 (IL-1), tumor necrosis factor (TNF) and interleukin-6 (IL-6). These results suggested that CH65 could act as a potential RA autoantigen [74].

Human cartilage glycoprotein-39 (HC gp-39)

Chondrocytes and synovial cells derived from RA patients secrete a 39 kDa glycoprotein named HC gp-39, which belongs to chitinase protein family, but does not possess activity against chitinase substrates. This autoantigen, which may act as an autoantigen in the immune response that develops in patients with RA, was rarely expressed in healthy people [75]. HC gp-39 is one of the major proteins produced and secreted by cultured articular chondrocytes and synovial fibroblasts. But neither the protein nor mRNA for HC gp-39 was detectable in normal newborn or adult human articular cartilage, while mRNA for this protein was detected both in synovial specimens and in cartilage obtained from patients with RA. It can be related to a response of the cells of articular cartilage and synovium to an inflammatory process [76]. It was also shown that the level of HC gp-39 was significantly higher in the plasma of RA patients than in the OA, SLE (systemic lupus erythematosus), or IBD (inflammatory bowel disease) patients and healthy control individuals. Moreover, the level of HC gp-39 in plasma of RA patients positively correlated with ESR (erythrocyte sedimentation rate) and IgM rheumatoid factor level. The level of HC gp-39 in the plasma of patients with OA, SLE, and IBD was also higher than in healthy controls, but no correlation was found with the disease activity score. Probably, the increased level of HC gp-39 did not only reflect the degree of joint disease but was related to inflammation and tissue degradation [77]. It has been demonstrated that the HC-gp mRNA level was higher in PBMC and synovium cells of RA patients than OA, SpA (spondyloarthropathy), SLE patients, and healthy control individuals. There were no significant differences among OA, SpA, SLE, and healthy controls [78]. To explain the role of HC gp-39 in matrix turnover and degradation the human skin fibroblasts and articular chondrocytes were stimulated with IL-1 and TNF in the presence of HC gp-39. It was shown that HC gp-39 suppressed the cytokine-induced production and secretion of metalloproteinases MMP1, MMP3, MMP13, and interleukine-8 (IL-8). Thus, HC gp-39 may play a role in limiting the catabolic effect of pro-inflammatory cytokines that are responsible for pathological loss of ECM, particularly that of cartilage in inflammatory and degenerative arthritis [79]. The other data also indicated that HC gp-39 participated in maintaining the balance between pro-inflammatory and regulatory responses in humans. PBMC from healthy individuals reacted against HC gp-39 with the production of interleukin-10 (IL-10) but not IFN-. Moreover, CD4+ T cell lines directed against HC gp-39 expressed CD25, glucocorticoid-induced tumour necrosis factor receptor (GITR), and forkhead box protein 3 (Foxp3) molecules (markers of regulatory T cells – Treg) and were capable of suppressing antigen-specific recall T cell responses. In contrast, the HC gp-39-directed immune response in 50% of RA patients exhibited polarisation toward a pro-inflammatory Th1 phenotype and was not as effective in suppressing antigen-specific recall responses. These findings indicated that the presence of HC gp-39-specific immune responses in healthy individuals might have an inhibitory effect on inflammatory responses. Furthermore, these data suggested that HC gp-39-directed immune response in RA patients had shifted from an anti-inflammatory to a pro-inflammatory phenotype [80]. In the early phase of the GPI (glucose-6-phosphate isomerase)-induced arthritis in mice, the serum level of HC gp-39 increased and its mRNA level increased in splenic CD4+CD25+ Foxp3+ regulatory T cells, but not in Th1, Th2, or Th17 cells. Furthermore, the addition of recombinant HC gp-39 caused the suppression of T-cell proliferation, and IFN- and interleukin-17 (IL-17) production. It suggested that HC gp-39 in CD4+ T cells might play a regulatory role in RA [81]. Studies of the presentation of immunodominant epitope of HC gp-39 by shared epitope-positive synovial dendritic cells indicated that this presentation was associated with characteristic histologic features of follicular synovitis and is highly specific for RA [82]. Autoantibodies against HC gp-39 were detected only in the sera of 8% of RA patients, but not in samples from SLE patients or healthy donors [83].

Rheumatoid arthritis-associated antigen 47 (RA-A47)

The serum levels of antibodies directed against numerous proteins were relatively high in RA patients, whose joints exhibited a high degree of erosion, but the antibodies against 47 kDa protein appeared at an early state of disease and were continuously produced at high levels relative to controls. This protein was isolated, characterised, and identified as a colligin2/HSP47 (heat shock protein 47), a collagen binding protein, and named RA-A47 – rheumatoid arthritis-associated antigen [84]. It belongs to the serpin family and serves as a chaperone protein for collagen type I, II, III, IV, and V and is localised exclusively in endoplasmic reticulum (ER) [85]. HSP47 binds to the procollagen after it enters the ER, forms triple helix, and proceeds to the Golgi apparatus, where HSP47 dissociates from it and procollagen is secreted. This protein is involved in processing and secretion of collagens with correct conformation and prevents the secretion of abnormal procollagens [86]. The expression of HSP47 has been shown to be raised together with the expression of COL2A1 (type II collagen) gene upon stimulation with transforming growth factor- (TGF-). Pro-inflammatory cytokines – TNF, interferon- (IFN-), and IL-6, however, down-regulate the expression of HSP47, without repression of COL2A1. It was also shown that surface type II collagen disappeared in chondrocytes after TNF stimulation. Probably the decreased expression of HSP47 might inhibit type II collagen secretion and its accumulation inside the cell. TNF stimulated also the synthesis of iNOS (inducible nitric oxide [NO] synthase) and MMP9. These observations demonstrated that under the influence of TNF HSP47 was down-regulated, and secreted type II collagen was not accumulated inside the cell, while ECM was degraded by MMPs and iNOS; NO has been demonstrated to activate nuclear factor-B (NF-B), an important transcription factor that promotes the inflammatory response [87]. The localisation of HSP47 was also changed, to the surface or outside of the cells, and this change was probably responsible for the recognition of HSP47 as an RA-A47 – autoantigen in RA [88]. The treatment of the cells with ra-a47-specific anti-sense oligonucleotide resulted in down-regulation of total RA-A47 expression, and its increased presence on the cell surface. The cell surface expression of CD9 (a 1 integrin-associated transmembrane protein involved in cell adhesion and motility) was also enhanced. CD9 was colocalised on the cell surface with RA-A47. Furthermore, the FITC-labelled annexin V was bound to the cell surface, and active forms of caspase 9 and 7 were detected. Thus, the down-regulation of RA-A47, a chaperone protein, might induce apoptosis. The surface-exposed RA-A47 induced autoantibodies production and inflammatory reactions in autoimmune diseases, e.g. RA [89].

Hyaluronan binding adhesion molecule CD44

Articular chondrocytes expressed the CD44, a multifunctional adhesion molecule that binds to hyaluronan (HA), type I collagen, and fibronectin. CD44 receptors are broadly distributed, and their binding evokes numerous responses. These include cell adhesion, cell migration, induction (or at least support) of haematopoietic differentiation, changes in other cell adhesion mechanisms, and interaction with cell activation signals. This diversity of responses indicates that downstream events following ligand binding by CD44 can be different depending on the cell type and on the environment of that cell. In mature lymphocytes, CD44 is up-regulated in response to antigenic stimuli and may participate in the effector stage of immunological responses. CD44 ligand-binding function on lymphocytes is strictly regulated, such that most CD44-expressing cells do not constitutively bind ligand. Ligand-binding function may be activated as a result of differentiation, inside-out signalling, and/or extracellular stimuli. CD44 is not a single molecule, but instead a diverse family of molecules generated by alternate splicing of multiple exons of a single gene and by different posttranslational modifications in different cell types. It is not yet clear how these modifications influence ligand-binding function [90]. CD44 receptors expressed on chondrocytes probably allow them to detect changes in matrix composition [91]. Thus, CD44 receptors play a critical role in maintaining cartilage homeostasis. Changes in interactions, either experimentally induced or detected in OA and RA, had profound effects on cartilage metabolism. The number of CD44-positive articular chondrocytes in RA was significantly higher than in OA, but the CD44 expression displayed a more distinct zonal variation in OA than in normal articular cartilage [92]. It has been demonstrated that anti-CD44 monoclonal antibody reacted with all CD44 isoforms and markedly reduced the inflammatory activity of arthritis induced by collagen in mice [93]. Therefore, up-regulation of CD44 on articular chondrocytes in RA and changes in expression of this molecule on OA chondrocytes may play a significant role in cartilage degeneration [94, 95].

Thymocyte antigen-1 (Thy-1) – CD90

A new cell surface molecule, Thy-1 (thymocyte antigen-1) or CD90, expressed by human articular chondrocytes and synovial fibroblasts has recently been identified. This molecule is a heavily N-glycosylated, 25-37 kDa GPI (glycosylphosphatidylinositol)-anchored protein discovered as a thymocyte antigen. It regulates cell adhesion, migration, differentiation, and survival [96]. OA cartilage showed a higher expression of CD90 than normal tissue. Additionally, is has been shown that in vitro stimulation with pro-inflammatory cytokine IL-1 up-regulated its expression in the cartilage. These results suggested that Thy-1 might be a potential biomarker for cartilage pathogenesis, degradation, and metabolic turnover [97, 98]. Fibroblasts positive for CD90 were enriched in the synovium of RA patients [99], but only a minority of RA articular chondrocytes displayed a moderate CD90 expression [98].

Signal transducer – CD24

The next detected on the surface of chondrocytes surface glycoprotein anchored via GPI link to the cell was CD24. This protein contributes to a wide range of downstream signalling networks and is crucial in cell differentiation. High expression of CD24 molecule was observed on juvenile chondrocytes, which demonstrate higher cell proliferation rate and extracellular matrix production as compared to the adult chondrocytes, which exhibit only low expression of CD24. The loss of CD24 in adult chondrocytes led to an increase of NFB activation and increased inflammatory and catabolic gene expression both in the presence and in the absence of IL-1. Thus, CD24 is the regulator of inflammatory response that is altered during development and aging. Since inflammaging is associated with many forms of age-related pathological conditions and age is a risk factor in RA and OA, the restoration of the juvenile expression of CD24 on articular chondrocytes would be one of the targets of future therapy [100].

Lymphocyte function-associated antigen-3 (LFA-3) – CD58

The next antigen strongly expressed on some RA, moderately on OA chondrocytes, and not detected on normal articular chondrocytes is CD58. It is a cell adhesion molecule expressed on professional APCs, particularly monocytes/macrophages [98]. The ligand for CD58 is CD2, an adhesion molecule present on CD4+ and CD8+ T lymphocytes and NK cells. The CD2/CD58 binding is involved in most T-cell interactions with the other cells and in T-cell activation. Moreover, the binding of CD2/CD58 has significant importance in autoimmune diseases such as RA because it plays a crucial role in lymphocyte recruitment to the inflammatory sites [101, 102]. The levels of soluble form of CD58 (sCD58) were found to be significantly reduced in sera and synovial fluid of RA patients in relation to healthy donors and patients with SpA. The reduction of serum sCD58 correlated significantly with clinical and laboratory parameters of disease. Because locally released sCD58 blocks CD2/CB58 interaction, insufficient amounts of sCD58 in synovitis might result in T-cell accumulation and perpetuation of inflammation [103].

Type I transmembrane protein Tmp21

Osiecka-Iwan et al. [49, 104] found that chondrocyte-associated antigen, sialylated form of transmembrane protein Tmp21, was expressed on the surface of rat chondrocytes from articular-epiphyseal complexes. Tmp21 belongs to the p24 protein family. These proteins mainly participate in the traffic between the ER and Golgi complex, but in some cells they appear also in membranes of secretory vacuoles and on cell surfaces. Sialylated Tmp21 decreased in cultured chondrocytes concomitantly with the decline of collagen type II and aggrecan and the rise of collagen type I and versican expression. Moreover, its expression returned in chondrocyte re-cultured in three-dimensional cell culture together with the expression of collagen type II and aggrecan [105]. Because the sialylated form of Tmp21 has not been detected in other tissues, Tmp21 with its sialylated oligosaccharide moiety could be a chondrocyte differentiation antigen [49]. Because rat chondrocytes transplanted intramuscularly to rabbit evoked the production of antibodies directed against sialylated form of Tmp21 present on chondrocytes, it could be the target of further investigations on the role of this molecule in autoimmune diseases, such as RA.

Immunosuppressive and immunomodulatory properties of chondrocytes

Although chondrocytes express MHC class I and class II molecules [7], more recent observations suggest that they can also exert immunosuppressive and immunomodulatory effects on immunocompetent cells. In 1992 Jobanputra et al. [106] demonstrated that non-stimulated isolated human articular chondrocytes constitutively expressed MHC class I, MHC class II, and ICAM molecules and were able to substitute monocytes in triggering T-cell proliferation to mitogenic polyclonal stimuli, such as phytohaemagglutinin A (PHA), they did not trigger, an efficient allogeneic immune response. Furthermore, IFN- and IL-1 treatment enhanced expression of MHC class II molecules and ICAM, but chondrocytes still failed to stimulate allogeneic PBMC. Contrary to previous authors, Adkinson et al. [18] found that isolated human articular chondrocytes did not constitutively express MHC class II molecules. Moreover, they did not express B7-1 (CD80) and B7-2 (CD86) molecules that provide a co-stimulatory signal necessary for T-cell activation, and suppressed, in a contact-dependent manner, proliferation of activated T cells. This suppression was associated with the expression of multiple negative regulators of immune responses. Adkinson et al. [18] detected that chondrocytes expressed other members of B7 peripheral membrane protein family, responsible for the inhibition of T-cell proliferation: programmed death-ligand 1 (PD-L1, B7-H1, CD274), programmed death-ligand 2 (PD-L2, B7-DC, CD273), B7-H2 (also called inducible co-stimulator-ligand – ICOS-ligand, CD275), B7-H3 (CD276), and V-domain Ig suppressor of T cell activation (VISTA, B7-H4). B7 molecules are membrane proteins found on activated antigen-presenting cells (APC), which bind to lymphocyte receptors CD28 or CD152 (cytotoxic T-lymphocyte-associated protein 4 – CTLA-4) and send a co-stimulatory or a co-inhibitory signal to enhance or decrease the activity of a MHC-TCR signal between the APC and the T cell [107]. Adkinson et al. [17] found that human chondrocytes expressed chondromodulin-I and indoleamine 2,3-dioxygenase (IDO). Chondromodulin-I is a cysteine-rich transmembrane protein originally purified from bovine epiphyseal cartilage that promotes chondrocyte proliferation [108, 109]. Mature protein can impact T-cell development or function; thus, chondromodulin-I expression by chondrocytes may directly disrupt T-cell function. IDO is the first and rate-limiting enzyme of tryptophan catabolism through the kynurenine pathway and has been implicated in immune modulation through its ability to limit T-cell function and engagement of mechanisms of immune tolerance [110]. The expression of mRNA for IDO was found also in human juvenile articular chondrocytes after IFN- treatment [14]. Similarly to Adkinson et al. [18], Lim et al. [14] found that isolated human juvenile articular chondrocytes expressed only MHC class I but not MHC class II and co-stimulatory molecules: B7-1 and B7-2. Also, these authors [14] observed that human chondrocytes expressed low levels of mRNA co-inhibitory molecule PD-L2. IFN- treatment of chondrocytes up-regulated the expression of PD-L2 and induced the expression of MHC class II molecules and co-inhibitory PD-L1 [14].
Some recent studies have shown that although articular chondrocytes expressed MHC class I molecules [14, 18], they did not stimulate alloantigen specific T-cell proliferation, but rather suppressed alloreactive T cells. This suppression was presumably mediated through the cell-to-cell contact with involvement of PD-L1 and PD-L2. Blocking of PD-L1 and/or PD-L2 with specific neutralising antibodies led to the restoration of alloreactive T-cell proliferation [14]. PD-L1 and PD-L2 probably promote self-tolerance and play a major role in suppressing the immune system during pregnancy, tissue allografts rejection, or autoimmune diseases. The binding of PD-L1 and PD-L2 to PD-1 transmits an inhibitory signal that reduces the proliferation of T cells and can also induce apoptosis by the regulation of the gene Bcl-2 expression [111, 112].
Similarly to previous authors, Lohan et al. [19] found that freshly isolated rat articular chondrocytes expressed low levels of MHC class I and negligible levels of MHC class II, CD80, and CD86 molecules. This expression was altered under the influence of oxygen tension and inflammatory cytokines (IFN- and TNF), but both primary and cytokine-stimulated cultured chondrocytes suppressed allogeneic T-cell proliferation in mixed lymphocyte/chondrocyte reaction. This inhibition could be dependent on decreased NO production [19]. NO probably represents an additional co-stimulatory signal for the induction of T cells [113]. Chondrocytes also have the ability to modulate inflammatory macrophage activity. The co-culture of macrophages and chondrocytes caused down-regulation of MHC class II molecules on lipopolysaccharide (LPS) or IFN--stimulated macrophages [19]. Pereira et al. [13] demonstrated that although human articular chondrocytes expressed a low level of MHC class I and II molecules, they markedly inhibited T-lymphocyte proliferation to antigen-dependent and -independent proliferative stimuli. Moreover, chondrocytes inhibited the differentiation of peripheral blood monocytes to professional antigen-presenting cells [13].
Abbe et al. [21] found that OA chondrocytes have similar surface antigens as those from the healthy donors. Almost all studied cells expressed MHC class I molecules. Only 1 to 2% of chondrocytes expressed MHC class II molecules and less than 1% co-stimulatory molecules CD80 and CD86. OA chondrocytes inhibited proliferation of activated CD4+ T cells in vitro via cell-cell contact and failed to elicit allogeneic CD8+ T-cell reaction [21]. They also inhibited proliferation of lymphocytes stimulated by allogeneic antigens. This effect was observed even if recombinant IL-2 was added to the lymphocyte-chondrocyte culture. Thus, human articular chondrocytes could induce IL-2 non-responsiveness of allogeneic lymphocytes [114].


Therefore, although the numerous data on chondrocyte expression of class I and II MHC molecules and co-stimulatory and co-inhibitory surface molecules have been collected, it should be stressed that many of them were obtained as the results of in vitro studies and may not be directly applicable to the in vivo situation. Therefore, it is probably unavoidable to verify them in clinical application and/or experiments with animal involvement.
The authors declare no conflict of interest.


1. Moskalewski S, Kawiak J (1965): Cartilage formation after homotransplantation of isolated chondrocytes. Transplantation 3: 737-747.
2. Moskalewski S, Hyc A, Osiecka-Iwan A (2002): Immune response by host after allogeneic chondrocyte transplant to the cartilage. Microsc Res Tech 1: 3-13.
3. Gibson T, Davis WB, Curran RC (1958): The long-term survival of cartilage homografts in man. Br J Plast Surg 11: 177-187.
4. Moskalewski S, Kawiak J, Rymaszewska T (1966): Local cellular response evoked by cartilage formed after auto- and allogeneic transplantation of isolated chondrocytes. Transplantation 4: 572-581.
5. Moskalewski S, Kawiak J (1965): Cartilage formation after transplantation of isolated chondrocytes. Transplantation 3: 737-747.
6. Ksiazek T, Moskalewski S (1983): Studies on bone formation by cartilage reconstructed by isolated epiphyseal chondrocytes, transplanted syngeneically or across known histocompatibility barriers in mice. Clin Orthop Relat Res 172: 233-242.
7. Brittberg M, Nilsson A, Lindahl A, et al. (1996): Rabbit articular cartilage defects treated with autologous cultured chondrocytes. Clin Orthop Relat Res 326: 270-283.
8. Moskalewski S, Osiecka-Iwan A, Hyc A, Niderla J (2005): Cartilage formed by syngeneic rat chondrocytes in joint surface defects is rejected in animals sensitized with allogeneic chondrocytes: involvement of the synovial lining. Arch Immunol Ther Exp 53: 159-168.
9. Osiecka A, Malejczyk J, Moskalewski S (1990): Cartilage transplants in normal and preimmunized mice. Arch Immunol Ther Exp 38: 461-473.
10. Romaniuk A, Malejczyk J, Kubicka U, et al. (1995): Rejection of cartilage formed by transplanted allogeneic chondrocytes: evaluation with monoclonal antibodies. Transpl Immunol 3: 251-257.
11. Elves MW (1974) A study of the transplantation antigens on chondrocytes from articular cartilage. J Bone Joint Surg Br 56: 178-185.
12. Tiku ML, Liu S, Weaver CW, et al. (1985): Class II histocompatibility antigen-mediated immunologic function of normal articular chondrocytes. J Immunol 135: 2923-2928.
13. Lance EM1, Kimura LH, Manibog CN (1993): The expression of major histocompatibility antigens on human articular chondrocytes. Clin Orthop Relat Res 291: 266-282.
14. Pereira RC, Martinelli D, Cancedda R, et al. (2016): Human articular chondrocytes regulate immune response by affecting directly T cell proliferation and indirectly inhibiting monocyte differentiation to professional antigen-presenting cells. Front Immunol 7: 415.
15. Lim CL, Lee YJ, Cho JH, et al. (2017): Immunogenicity and immunomodulatory effects of the human chondrocytes, hChonJ. BMC Musculoskelet Disord 18: 199.
16. Malejczyk J, Romaniuk A (1989): Reactivity of normal rat epiphyseal chondrocytes with monoclonal antibodies recognizing different leucocyte markers. Clin Exp Immunol 75: 477-480.
17. Bujia J, Wilmes E, Krombach F, et al.(1990): The effect of gamma-interferon on HLA class II antigen expression on isolated human nasal chondrocytes. Eur Arch Otorhinolaryngol 247: 287-290.
18. Bujia J, Alsalameh S, Sittinger M, et al. (1994): Antigen presenting cell function of class II positive human nasal chondrocytes. Acta Otolaryngol (Stockh) 114: 75-79.
19. Adkisson, C Milliman, X Zhang, et al. (2010): Immune evasion by neocartilage-derived chondrocytes: Implications for biologic repair of joint articular cartilage. Stem Cell Res 4: 57-68.
20. Lohan P, Treacy O, Lynch K, et al. (2016): Culture expanded primary chondrocytes have potent immunomodulatory properties and do not induce an allogeneic immune response. Osteoarthritis and Cartilage 24: 521-533.
21. Burmester GR, Menche D, Merryman P, et al (1983): Application of monoclonal antibodies to the characterization of cell eluted from human articular cartilage. Atrhritis Rheum 26: 1187-1195.
22. Abe S, Nochi H, Ito H (2016): Alloreactivity and immunosuppressive properties of articular chondrocytes from osteoarthritic cartilage. J Orthop Surg (Hong Kong) 24: 232-239.
23. Alsalameh S, Jahn B, Krause A, Kalden JR, et al. (1991): Antigenicity and accessory cell function of human articular chondrocytes. J Rheumatol 18: 414-421.
24. Malejczyk J, Kamiński MJ, Malejczyk M, Majewski S (1985): Natural cell-mediated cytotoxic activity against isolated chondrocytes in the mouse. Clin Exp Immunol 59: 110-116.
25. DM Radomska, A Osiecka, J Malejczyk (1989): Natural cell-mediated cytotoxicity against syngeneic rat chondrocytes originating from different types of cartilage. Immunol Cell Biol 67: 209-213.
26. Yamaga KM, Bolen H, Kimura L, Lance EM (1993): Enhanced chondrocyte destruction by lymphokine-activated killer cells. Possible role in rheumatoid arthritis. Arthritis Rheum 36: 500-513.
27. Sommaggio R1, Cohnen A, Watzl C, Costa C (2012) Multiple receptors trigger human NK cell-mediated cytotoxicity against porcine chondrocytes. J Immunol 188: 2075-2083.
28. Białoszewska A, Baychelier F, Niderla-Bielińska J, et al. (2013): Constitutive expression of ligand for natural killer cell NKp44 receptor (NKp44L) by normal human articular chondrocytes. Cell Immunol 285: 6-9.
29. Hecht ML, Rosental B, Horlacher T, et al. (2009): Natural cytotoxicity receptors NKp30, NKp44 and NKp46 bind to different heparan sulfate/heparin sequences. J Proteome Res 8: 712-720.
30. Dalbeth N, Callan MF (2002): A subset of natural killer cells is greatly expanded within inflamed joints. Arthritis Rheum 46: 1763-1772.
31. Conigliaro P, Scrivo R, Valesini G, Perricone R (2011): Emerging role for NK cells in the pathogenesis of inflammatory arthropathies. Autoimmun Rev 10: 577-581.
32. Białoszewska A, Niderla-Bielińska J, Hyc A, et al. (2009): Chondrocyte-specific phenotype confers susceptibility of rat chondrocytes to lysis by NK cells. Cell Immunol 258: 197-203.
33. Białoszewska A, Olkowska-Truchanowicz J, Bocian K, et al. (2018): A Role of NKR-P1A (CD161) and Lectin-like Transcript 1 in Natural Cytotoxicity against Human Articular Chondrocytes. J Immunol 200: 715-724.
34. Bezouska K (1996): C-type lectins of natural killer cells: carbohydrate ligands and role in tumour cell lysis. Biochem Soc Trans 24: 156-161.
35. Rosen DB, Cao W, Avery DT, Tangye SG, et al. (2008): Functional consequences of interactions between human NKR-P1A and its ligand LLT1 expressed on activated dendritic cells and B cells. J Immunol 180: 6508-6517.
36. Mankin HJ (1982): The response of articular cartilage to mechanical injury. J Bone Joint Surg Am 64: 460-466.
37. Metsäranta M, Kujala UM, Pelliniemi L, et al. (1996): Evidence for insufficient chondrocytic differentiation during repair of full-thickness defects of articular cartilage. Matrix Biol 15: 39-47.
38. Brittberg M, Lindahl A, Nilsson A, et al. (1994): Treatment of deep cartilage defects in the knee with autologous chondrocyte transplantation. N Engl J Med 331: 889-895.
39. Robinson D, Ash H, Aviezer D, et al. (2000) Autologous chondrocyte transplantation for reconstruction of isolated joint defects: the Assaf Harofeh experience. Isr Med Assoc J 2: 290-295.
40. Roberts S, McCall IW, Darby AJ, et al. (2003): Autologous chondrocyte implantation for cartilage repair: monitoring its success by magnetic resonance imaging and histology. Arthritis Res Ther 5: R60-73.
41. Behrens P, Bitter T, Kurz B, Russlies M (2006): Matrix-associated autologous chondrocyte transplantation/implantation (MACT/MACI)--5-year follow-up. Knee 13: 194-202.
42. Hinckel BB, Gomoll AH (2017): Autologous Chondrocytes and Next-Generation Matrix-Based Autologous Chondrocyte Implantation. Clin Sports Med 36: 525-548.
43. Nameroff M, Holtzer H (1967): The loss of phenotypic traits by differentiated cells. IV. Changes in polysaccharides produced by dividing chondrocytes. Dev Biol 16: 250-281.
44. Chacko S, Abbott J, Holtzer S, Holtzer H (1969): The loss of phenotypic traits by differentiated cells. VI. Behavior of the progeny of a single chondrocyte. J Exp Med 130: 417-442.
45. Schlitz JR, Mayne R, Holtzer H (1973): The synthesis of collagen and glycosaminoglycans by dedifferentiated chondrocytes in culture. Differentiation 1: 97-108.
46. Mayne R, Vail MS, Maine PM, Miller EJ (1976): Changes in type of collagen synthesis as clones of chick chondrocyte grow and eventually lose division capacity. Proc Natl Acad Sci USA 73: 1674-1678.
47. Sgaglione NA (2005: Biologic Approaches to Articular Cartilage Surgery: Future Trends Orthop Clin North Am 36: 485-495.
48. Benya PD, Shaffer JD (1982): Dedifferentiated chondrocytes reexpress the differentiated collagen phenotype when cultured in agarose gels. Cell 30: 215-224.
49. Bonaventure J, Kadhom N, Cohen-Solal L, Ng KH, Bourguignon J, Lasselin C (1994): Reexpression of cartilage-specific genes by dedifferentiated human articular chondrocytes cultured in alginate beads. Exp Cell Res 212: 97-104.
50. Osiecka-Iwan A, Niderla-Bielinska J, Hyc A, Moskalewski S (2014): Rat Chondrocyte-Associated Antigen Identified as Sialylated Transmembrane Protein Tmp21 Belonging to the p24 Protein Family. Calcif Tissue Int 94: 348-352.
51. Hyc A, Malejczyk J, Osiecka A, Moskalewski S (1997): Immunological response against allogeneic chondrocytes transplanted into joint surface defects in rats. Cell Transplant 6: 119-124.
52. Shibuya N, Imai Y, Lee YS, et al. (2014): Acute Rejection of Knee Joint Articular Cartilage in a Rat Composite Tissue Allotransplantation Model. J Bone Joint Surg Am 96: 1033-1039.
53. Osiecka-Iwan A, Hyc A, Moskalewski S (1999): Immunosuppression and rejection of cartilage formed by allogeneic chondrocytes in rats. Cell Transplant 8: 627-636.
54. Moskalewski S, Osiecka-Iwan A, Hyc A, Jozwiak J (2000): Mechanical barrier as a protection against rejection of allogeneic cartilage formed in joint surface defects in rats. Cell Transplant 9: 349-357.
55. Moskalewski S, Osiecka-Iwan A, Hyc A (2001): Cartilage produced after transplantation of syngeneic chondrocytes is rejected in rats presensitized with allogeneic chondrocytes. Cell Transplant 10: 625-632.
56. Langer F, Gross AE, Greaves MF (1972): The auto-immunogenicity of articular cartilage. Clin Exp Immunol 12: 31-37.
57. Gertzbein SD, Tait JH, Devlin SR, Argue S (1977): The antigenicity of chondrocytes. Immunology 33: 141-145.
58. Lance EM (1989): Immunological reactivity towards chondrocytes in rat and man: relevance to autoimmune arthritis. Immunol Lett 21: 63-73
59. Glant T, Mikecz K (1986): Antigenic profiles of human, bovine and canine articular chondrocytes. Cell Tissue Res 244: 359-369.
60. Malseed ZM, Heyner S (1976): Antigenic profile of the rat chondrocyte. Arthritis Rheum 19: 223-231.
61. Jasin HE (1985): Autoantibody specificities of immune complexes sequestered in articular cartilage of patients with rheumatoid arthritis and osteoarthritis. Arthritis Rheum 28: 241-248.
62. Mollenhauer J, Brune K (1988): Detection of autoimmunoreactive antibodies against cartilage cell surface proteins in the blood of rheumatic patients. Agents Act 23: 1-2.
63. Mollenhauer J, von der Mark K, Burmester G, et al. (1988): Serum antibodies against chondrocyte cell surface proteins in osteoarthritis and rheumatoid arthritis. J Rheumatol 15: 1811-1817.
64. Takagi T, Jasin HE (1992): Interactions between anticollagen antibodies and chondrocytes. Arthritis Rheum 35: 224-230.
65. Mollenhauer J, von der Mark K (1983): Isolation and characterization of a collagen-binding glycoprotein from chondrocyte membranes. EMBO J 2: 45-50.
66. Von der Mark K, Mollenhauer J, Muller PK, Pfaffle M (1985): Anchorin CII, a type II collagen-binding glycoprotein from chondrocyte. Ann NY Acad Sci 460: 214-223.
67. Jasin HE (1994): The articular cartilage surface as a target organ. Clin Exp Rheum 12: 469-472.
68. Repraeger A, Bernfield M (1982): An integral membrane proteoglycan can bind the extracelluler matrix directly to the cytoskeleton (abstract). J Cell Biol 95: A125.
69. Hewitt AT, Varner HH, Silver MH, et al. (1982): The isolation and partial characterization of chondronectin, an attachment factor for chondrocytes. J Biol Chem 257: 2330-2334.
70. Salter DM, Hughes DE, Simpson R, Gardner DL (1992): Integrin expression by human articular chondrocytes. Br J Rheum 31: 231-234.
71. Sabbatini A, Tacchetti C, Tommasi S, et al. (2003) Use of human chondrocyte cell cultures to identify and characterize reactive antibodies in rheumatoid arthritis sera. Clin Exp Rheumatol 21: 587-592.
72. Paróczai C, Németh-Csóka M (1988): Estimation of serum anticollagen and the antibodies against chondrocyte membrane fraction: their clinical diagnostic significance in osteoarthritis. Clin Biochem 21: 117-121.
73. Kirstein H, Mathiesen FK (1987): Antikeratin antibodies in rheumatoid arthritis. Methods and clinical significance. Scand J Rheumatol 16: 331-338.
74. Bang H, Mollenhauer J, Schulmeister A, et al. (1994): Isolation and characterization of a cartilage-specific membrane antigen (CH65): comparison with cytokeratins and heat-shock proteins. Immunology 81: 322-329.
75. Alsalameh RJ, Casey RC, Mollenhauer J, et al. (2017): Induction of proliferation and pro-inflammatory cytokine production in rheumatoid arthritis peripheral blood mononuclear cells by a 65 KDa chondrocyte membrane-specific, constitutive target autoantigen (CH65). Int J Rheum Dis 20: 1132-1141.
76. Verheijden GF, Rijnders AW, Bos E, et al. (1997): Human cartilage glycoprotein-39 as a candidate autoantigen in rheumatoid arthritis. Arthritis Rheum 40: 1115-1125.
77. Hakala BE, White C, Recklies AD (1993): Human cartilage gp-39, a major secretory product of articular chondrocytes and synovial cells, is a mammalian member of a chitinase protein family. J Biol Chem 268: 25803-25810.
78. Vos K, Steenbakkers P, Miltenburg AM, et al. (2000): Raised human cartilage glycoprotein-39 plasma levels in patients with rheumatoid arthritis and other inflammatory conditions. Ann Rheum Dis 59: 544-548.
79. Shen M, Zeng XJ, Tang FL (2004): Human cartilage glycoprotein 39 mRNA expression in peripheral blood and synovium mononuclear cells in rheumatoid arthritis. Zhonghua Nei Ke Za Zhi 12: 928-931.
80. Ling H1, Recklies AD (2004): The chitinase 3-like protein human cartilage glycoprotein 39 inhibits cellular responses to the inflammatory cytokines interleukin-1 and tumour necrosis factor-alpha. Biochem J 380 (Pt 3): 651-659.
81. van Bilsen JH, van Dongen H, Lard LR, et al. (2004): Functional regulatory immune responses against human cartilage glycoprotein-39 in health vs. proinflammatory responses in rheumatoid arthritis. Proc Natl Acad Sci USA 101: 17180-17185.
82. Tanaka Y, Matsumoto I, Inoue A, et al. (2014): Antigen-specific over-expression of human cartilage glycoprotein 39 on CD4+ CD25+ forkhead box protein 3+ regulatory T cells in the generation of glucose-6-phosphate isomerase-induced arthritis. Clin Exp Immunol 177: 419-427.
83. Baeten D, Steenbakkers PG, Rijnders AM, et al. (2004): Detection of major histocompatibility complex/human cartilage gp-39 complexes in rheumatoid arthritis synovitis as a specific and independent histologic marker. Arthritis Rheum 50: 444-451.
84. Sekine T, Masuko-Hongo K, Matsui T, et al. (2001): Recognition of YKL-39, a human cartilage related protein, as a target antigen in patients with rheumatoid arthritis Ann Rheum Dis 60: 49-54.
85. Hattori T, Fujisawa T, Sasaki K, et al. (1998): Isolation and characterization of a rheumatoid arthritis-specific antigen (RA-A47) from a human chondrocytic cell line (HCS-2/8). Biochem Biophys Res Commun 245: 679-683.
86. Mala JG, Rose C (2010): Interactions of heat shock protein 47 with collagen and the stress response: an unconventional chaperone model?. Life Sciences 87: 579-586.
87. Razzaque MS, Taguchi T (1999): The possible role of colligin/HSP47, a collagen-binding protein, in the pathogenesis of human and experimental fibrotic diseases. Histol Histopathol 14: 1199-1212.
88. Kaibori M, Sakitani K, Oda M, et al. (1999): Immunosuppressant FK506 inhibits inducible nitric oxide synthase gene expression at a step of NF-B activation in rat hepatocytes. J Hepatol 30: 1138-1145.
89. Hattori T, Kubota S, Yutani Y, et al. (2001): Change in cellular localization of a rheumatoid arthritis-related antigen (RA-A47) with down-regulation upon stimulation by inflammatory cytokines in chondrocytes. J Cell Physiol 186: 268-281.
90. Hattori T, von der Mark K, Kawaki H, et al. (2005): Downregulation of rheumatoid arthritis-related antigen RA-A47 (HSP47/colligin-2) in chondrocytic cell lines induces apoptosis and cell-surface expression of RA-A47 in association with CD9. J Cell Physiol 202: 191-204.
91. Lesley J, Hyman R, Kincade PW (1993): CD44 and its interaction with extracellular matrix. Adv Immunol 54: 271-335.
92. Knudson W, Loeser RF (2002): CD44 and integrin matrix receptors participate in cartilage homeostasis Cell Mol Life Sci 59: 36-44.
93. Ostergaard K, Salter DM, Andersen CB, et al. (1997): CD44 expression is up-regulated in the deep zone of osteoarthritic cartilage from human femoral heads. The objective of this study was to detail the topographical and zonal distribution of the cell adhesion molecule CD44 in normal and osteoarthritic cartilage. Histopathology 31: 451-459.
94. Naor D, Nedvetzki S (2003): CD44 in rheumatoid arthritis. Arthritis Res Ther 5: 105-115. 94. Nakamura H, Kato R, Hirata A, et al. (2005): Localization of CD44 (hyaluronan receptor) and hyaluronan in rat mandibular condyle. Histochem Cytochem 53: 113-120.
95. Takagi T, Okamoto R, Suzuki K, et al. (2001): Up-regulation of CD44 in rheumatoid chondrocytes. Scand J Rheumatol 30: 110-113.
96. Bradley JE, Chan JM, Hagood JS (2013): Effect of the GPI anchor of human Thy-1 on antibody recognition and function. Lab Invest 93: 365-374.
97. Chanmee T, Phothacharoen P, Thongboonkerd V, et al. (2012): Characterization of monoclonal antibodies against a human chondrocyte surface antigen. Monoclon Antib Immunodiagn Immunother 32: 180-186.
98. Summers KL, O’Donnell JL, Hoy MS, Peart M, et al. (1995): Monocyte-macrophage antigen expression on chondrocytes. J Rheumatol 22: 1326-1334.
99. Slowikowski K, Wei K, Brenner MB, Raychaudhuri S (2018): Functional genomics of stromal cells in chronic inflammatory diseases Curr Opin Rheumatol 30: 65-71.
100. Lee J, Smeriglio P, Dragoo J, et al. (2016): CD24 enrichment protects while its loss increases susceptibility of juvenile chondrocytes towards inflammation. Arthritis Res Ther 18: 292.
101. Hoffmann JC, Bayer B, Zeidler H (1996): Characterization of a soluble form of CD58 in synovial fluid of patients with rheumatoid arthritis (RA). Clin Exp Immunol 104: 460-466.
102. Sable R, Durek T, Taneja V, et al. (2016): Constrained Cyclic Peptides as Immunomodulatory Inhibitors of the CD2:CD58 Protein-Protein Interaction. ACS Chem Biol 11: 2366-2374.
103. Hoffmann JC, Räuker HJ, Krüger H, et al. (1996): Decreased levels of a soluble form of the human adhesion receptor CD58 (LFA-3) in sera and synovial fluids of patients with rheumatoid arthritis. Clin Exp Rheumatol 14: 23-29.
104. A, Hyc A, Józwiak J, et al. (2003): Transplants of rat chondrocytes evoke strong humoral response against chondrocyte-associated antigen in rabbits. Cell Transplant 12: 389-398.
105. Osiecka-Iwan A, Hyc A, Niderla-Bielinska J, Moskalewski S (2008): Chondrocyte-associated antigen and matrix components in a 2- and 3-dimensional culture of rat chondrocytes. Mol Med Rep 1:881-887.
106. Jobanputra P, Corrigall V, Kingsley G, Panayi G (1992): Cellular responses to human chondrocytes: absence of allogeneic responses in the presence of HLA-DR and ICAM-1. Clin Exp Immunol 90: 336-344.
107. M Collins, V Ling, B M Carreno (2005): The B7 family of immune-regulatory ligands. Genome Biol 6: 223.
108. Hiraki Y, Inoue H, Iyama K, et al. (1997): Identification of chondromodulin I as a novel endothelial cell growth inhibitor. Purification and its localization in the avascular zone of epiphyseal cartilage. J Biol Chem 272: 32419-32426.
109. Inoue H, Kondo J, Koike T, et al. (1997): Identification of an autocrine chondrocyte colony-stimulating factor: chondromodulin-I stimulates the colony formation of growth plate chondrocytes in agarose culture. Biochem Biophys Res Commun 241: 395-400.
110. Munn DH, Mellor AL (2013): Indoleamine 2,3 dioxygenase and metabolic control of immune responses. Trends Immunol 34: 137-143.
111. Eyre TA, Collins GP (2015): Immune checkpoint inhibition in lymphoid disease. Br J Haematol 170: 291-304.
112. Fife BT, Pauken KE (2011): The role of the PD-1 pathway in autoimmunity and peripheral tolerance. Ann NY Acad Sci 1217: 45-59.
113. W Niedbala, B Cai, and F Y Liew (2006) Role of nitric oxide in the regulation of T cell functions. Ann Rheum Dis 65 (Suppl. 3): iii37-iii40.
114. Abe S, Nochi H, Ito H (2017): Human Articular Chondrocytes Induce Interleukin-2 Nonresponsiveness to Allogeneic Lymphocytes. Cartilage 8: 300-306.
Copyright: © 2018 Polish Society of Experimental and Clinical Immunology This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Quick links
© 2022 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.